The non-specific nuclease from Serratia marcescens is able to cleave all forms of DNA and RNA very efficiently. It is commonly used in biotechnology for the quantitative removal of nucleic acids and for viscosity reduction. In the pharmaceutical industry, the nuclease is often used to remove excess nucleic acids in production processes of biopharmaceuticals and vaccines.
c-LEcta has developed a patent-protected production technology for this enzyme based on the recombinant expression in Bacillus. The new production process combines high product yields with the advantages of an endotoxin-free production strain. In addition, the enzyme is manufactured under cGMP using only raw materials of non-animal origin.
The product is marketed under the brand name DENARASE by Sartorius Stedim Biotech, our sales and distribution partner for the biopharmaceutical industry.